Renovos secures £140k pre-seed investment from Orthopaedic Research UK to advance orthopaedic treatments.
Orthopaedic Research UK provided the pre-seed funding through the newly launched Ronald Furlong Fund.
Renovos develops regenerative medicine solutions using proprietary nanoclay gel technology to improve orthopaedic surgery outcomes. The company harnesses innovative delivery platforms to enhance tissue repair and bone healing.
Renovos has secured £140k in pre-seed funding from Orthopaedic Research UK to advance its regenerative medicine solutions. The investment marks the inaugural backing from the Ronald Furlong Fund, established in partnership with healthtech accelerator HS. The capital will support the biotech firm in addressing critical needs for patients suffering from bone and joint conditions.
From the founder
"We are delighted to receive support from ORUK, which will aid the development of our next generation orthopaedic regenerative medicine solutions, harnessing nanoclay gels to deliver bone forming agents safely and cost effectively. The partnership will significantly enhance Renovos’ ability to further develop innovative technologies to support the ageing population as well as younger, active individuals."
Richard OC Oreffo
Founder and CSO at Renovos
Investor perspective
"It quickly became apparent that Renovos has the potential to fundamentally change the way extremely powerful and sometimes harmful drugs are given around bone. During the interview phase we were impressed by the immense knowledge and expertise of the team and we’re now excited to join the journey and to use our networks to help take them to the next level."
James Somauroo
Founding Partner, HS
Use of funds
- 01Continue product development
- 02Fund research and development